Clinical Trials Browser

Phase 1 × lenvatinib × Clear all

NCT06858813 2026-03-25

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Phase 1 Recruiting

Gastrointestinal

Liver Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Phase 1 Recruiting

Endometrial Neoplasms

NCT05081180 2026-01-23

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1 Active not recruiting

Neoplasms, Central Nervous System Neoplasms

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms

NCT05030506 2025-12-18

MK-6482-010

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04427293 2025-12-16

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT03564691 2025-10-07

MK-4830-001

Phase 1 Completed

Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Phase 1 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT02720068 2025-05-30

MK-4280-001

Phase 1 Completed

481 enrolled 36 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT03524326 2025-05-13

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03324373 2025-04-24

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Phase 1 Completed

Carcinoma, Renal Cell

NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05803928 2024-07-24

Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03418922 2024-06-20

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

Phase 1 Completed

30 enrolled 28 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05533892 2023-12-19

CCGLC-007

Phase 1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03006926 2023-12-13

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Phase 1 Completed

104 enrolled 41 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05767684 2023-08-25

Neoantigen Derived DCs as Cancer Treatment

Phase 1 Unknown

Neoplasms

NCT00121719 2023-06-22

An Open Label Dose Escalation Study Of E7080

Phase 1 Completed

82 enrolled 34 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT01268293 2023-06-22

A Study of E7080 in Subjects With Solid Tumor

Phase 1 Completed

9 enrolled 6 charts

Neoplasms

NCT01525394 2023-06-22

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Phase 1 Completed

Lymphoma

NCT05675462 2023-03-06

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase 1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05225116 2023-02-08

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Phase 1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02788708 2022-09-19

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02935309 2022-05-31

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

Phase 1 Completed

Gastrointestinal

Carcinoma, Rectal Neoplasms

NCT05221775 2022-02-03

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Phase 1 Unknown

Gastrointestinal

First-line Treatment

NCT05171530 2021-12-29

Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer

Phase 1 Unknown

Gastrointestinal

HER2-negative Advanced Gastric Cancer

NCT03009292 2021-09-28

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT03006887 2021-05-20

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1 Completed

6 enrolled 27 charts

GenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Endometrial Neoplasms

NCT02686164 2019-08-28

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Phase 1 Completed

51 enrolled 11 charts

Neoplasms

NCT02454478 2019-03-19

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Phase 1 Completed

7 enrolled 17 charts

Carcinoma, Carcinoma, Renal Cell

NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Phase 1 Withdrawn

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT02578316 2017-06-20

A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.

Phase 1 Completed

6 enrolled 19 charts

Lymphoma

NCT00280397 2016-10-07

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Phase 1 Completed

27 enrolled 8 charts

Neoplasms

NCT00121680 2015-12-11

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Phase 1 Completed

Melanoma, Neoplasms

NCT00832819 2015-04-30

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

28 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01240408 2015-03-04

E7080 Food Effect Study in Healthy Subjects

Phase 1 Completed

Neoplasms